186 related articles for article (PubMed ID: 31030498)
41. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours.
Cookson VJ; Bentley MA; Hogan BV; Horgan K; Hayward BE; Hazelwood LD; Hughes TA
Cell Oncol (Dordr); 2012 Aug; 35(4):301-8. PubMed ID: 22821209
[TBL] [Abstract][Full Text] [Related]
42. miR-188-5p suppresses cellular proliferation and migration via IL6ST: A potential noninvasive diagnostic biomarker for breast cancer.
Wang M; Zhang H; Yang F; Qiu R; Zhao X; Gong Z; Yu W; Zhou B; Shen B; Zhu W
J Cell Physiol; 2020 May; 235(5):4890-4901. PubMed ID: 31650530
[TBL] [Abstract][Full Text] [Related]
43. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
[TBL] [Abstract][Full Text] [Related]
44. Plasma exosome microRNAs are indicative of breast cancer.
Hannafon BN; Trigoso YD; Calloway CL; Zhao YD; Lum DH; Welm AL; Zhao ZJ; Blick KE; Dooley WC; Ding WQ
Breast Cancer Res; 2016 Sep; 18(1):90. PubMed ID: 27608715
[TBL] [Abstract][Full Text] [Related]
45. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
Dong LL; Chen LM; Wang WM; Zhang LM
Diagn Pathol; 2015 Apr; 10():45. PubMed ID: 25924779
[TBL] [Abstract][Full Text] [Related]
46. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O
Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
49. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
[TBL] [Abstract][Full Text] [Related]
50. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
[TBL] [Abstract][Full Text] [Related]
51. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
[TBL] [Abstract][Full Text] [Related]
52. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
Wu X; Somlo G; Yu Y; Palomares MR; Li AX; Zhou W; Chow A; Yen Y; Rossi JJ; Gao H; Wang J; Yuan YC; Frankel P; Li S; Ashing-Giwa KT; Sun G; Wang Y; Smith R; Robinson K; Ren X; Wang SE
J Transl Med; 2012 Mar; 10():42. PubMed ID: 22400902
[TBL] [Abstract][Full Text] [Related]
53. Effects of differential distribution of microvessel density, possibly regulated by miR-374a, on breast cancer prognosis.
Li JY; Zhang Y; Zhang WH; Jia S; Kang Y; Tian R
Asian Pac J Cancer Prev; 2013; 14(3):1715-20. PubMed ID: 23679262
[TBL] [Abstract][Full Text] [Related]
54. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
55. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women.
Motawi TM; Sadik NA; Shaker OG; El Masry MR; Mohareb F
Gene; 2016 Sep; 590(2):210-9. PubMed ID: 26827795
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer.
Su ZX; Zhao J; Rong ZH; Wu YG; Geng WM; Qin CK
Tumour Biol; 2014 Dec; 35(12):12119-25. PubMed ID: 25416437
[TBL] [Abstract][Full Text] [Related]
57. Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma.
Singh P; Srivastava AN; Sharma R; Mateen S; Shukla B; Singh A; Chandel S
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1053-1057. PubMed ID: 29699056
[TBL] [Abstract][Full Text] [Related]
58. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
59. Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Liu W; Xu Y; Guan H; Meng H
Cancer Biomark; 2018; 22(3):487-493. PubMed ID: 29843213
[TBL] [Abstract][Full Text] [Related]
60. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
